Research Programs-Radiobiology and Radiotherapy

研究项目-放射生物学和放射治疗

基本信息

批准号：
7513248
负责人：
PETER M GLAZER
金额：
$ 2.16万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-08-09 至 2012-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7513248
关键词：
ATM activation Address Alkylating Agents Alkylation Alternative Medicine American American Cancer Society Animal Model Animals Apoptosis Area Attention Award B-Cell Lymphomas BRCA1 gene BRCA2 gene Bacteria Base Excision Repairs Biogenesis Biological Biological Markers Biological Models Biology Biotechnology Black Cohosh Extract Bone Marrow Botanicals Brachytherapy Breast Breast Cancer Treatment CDT1 Gene Caenorhabditis elegans Cancer Center Cell Communication Cell Cycle Cell Nucleus Cells Cellular biology Center Core Grants Cervix Uteri Cervix carcinoma Chinese People Chromosomes Cimicifuga racemosa Cisplatin Class Clinical Clinical Research Clinical Trials Clonal Expansion Collaborations Complex Condition Cutaneous Cutaneous Lymphoma Cyclin A Cytotoxin DNA DNA Binding DNA Damage DNA Repair DNA Repair Enzymes DNA Replication Factor DNA Structure DNA photoproducts DNA-dependent protein kinase Databases Development Developmental Therapeutics Program Direct Costs Down-Regulation Doxorubicin Drops Drosophila genus Drug Formulations E2F Transcription Factor 1 Educational workshop Efaproxiral Effectiveness Enzymatic Biochemistry Enzymes Epidermal Growth Factor Receptor Eukaryotic Cell Exploratory/Developmental Grant for Diagnostic Cancer Imaging Facility Construction Funding Category Faculty Funding Future Gap Junctions Geminin Gene Expression Profile Gene Mutation Gene Targeting Genetic Genetic Recombination Genetic Transcription Goals Grant Growth Guanine H-DNA Head Head and Neck Cancer Head and neck structure Hemoglobin Hospitals Human Engineering Human Resources Hypersensitivity Hypoxia Image Infiltration Insulin-Like-Growth Factor I Receptor Investigation Ionizing radiation Joints Journals Laboratories Lead Leadership Lesion Linear Accelerator Radiotherapy Systems MEN1 gene MLH1 gene Magnetic Resonance Imaging Maintenance Malignant Neoplasms Malignant Squamous Cell Neoplasm Malignant neoplasm of prostate Mammalian Cell Medical Medicine Menopausal Symptom Metastatic malignant neoplasm to brain Methods Mismatch Repair Mitomycin Molecular Molecular Virology Morbidity - disease rate Multiple Endocrine Neoplasia Type 1 Mus Mutagenesis Mutation Nature New England Normal tissue morphology Nucleotide Excision Repair Numbers O(6)-Methylguanine-DNA Methyltransferase Oligonucleotides Oncogenic Oral Outcome Oxygen PHY 906 Paper Pathway interactions Patients Pattern Peer Review Pelvis Peptide Nucleic Acids Pharmaceutical Preparations Pharmacologic Substance Pharmacology Phase Phase III Clinical Trials Physicians Physics Play Poly(ADP-ribose) Polymerases Polymerase Polyploidy Population Porfiromycin Positioning Attribute Process Prodrugs Production Program Research Project Grants Property Prostate Proteins Proteolysis Publications Published Comment Publishing RSR-13 Rad51 recombinase Radiation Radiation Tolerance Radiation Toxicity Radiation therapy Radiation, Other Radio Radiobiology Radiometry Randomized Clinical Trials Range Reaction Recruitment Activity Regulation Regulatory Pathway Repair Complex Reporter Genes Reporting Research Research Personnel Resistance Resource Sharing Ribonucleoproteins Ribonucleotide Reductase Subunit Ribosomes Role Running Salmonella Schools Science Scientist Seeds Series Signal Transduction Pathway Site Skin Carcinogenesis Solid Neoplasm Son Source Specificity Structure Sunburn System TP53 gene Techniques Testing Therapeutic Therapeutic Radiology specialty Thymidine Phosphorylase Tissues Training Translational Research Treatment Protocols Triapine Tumor Biology Tumor Oxygenation Tumor Stem Cells UV induced United States National Institutes of Health Variant Viral Vision Work X-Ray Computed Tomography Yale Cancer Center Yeasts anticancer research base cancer cell differentiation cancer genetics cancer radiation therapy cancer therapy capecitabine carcinogenesis cell growth cell growth regulation cell transformation chemotherapy chromosome replication cone-beam computed tomography cost cytotoxic detector dosimetry fluoropyrimidine follow-up foot gene repair helicase immunoregulation improved in vivo indexing inhibitor/antagonist interest irradiation malignant breast neoplasm member metaplastic cell transformation millimeter mouse model mutant neoplastic novel oncology particle post-doctoral training pre-clinical preclinical study prognostic programs recombinase repaired research study response treatment duration treatment planning triplex DNA tumor tumor progression ubiquitin-protein ligase ultraviolet damage

项目摘要

The Program in Radiobiology and Radiotherapy (R&R) comprises a broadly based, multifaceted research effort in radiation therapy, radiation biology, radiological physics and related areas of tumor biology. This program has been an approved component of the Cancer Center Core Grant for over 20 years. Its long-term goal is to improve the treatment of cancer in general and in particular, the effectiveness of radiation therapy The program includes a broad spectrum of activity that extends from laboratory-based experimental research to clinical investigation and features investigators associated with eight departments. Some of the key themes include studies of carcinogenesis, genetic instability and cell growth control; elucidation of DNA repaii pathways; investigation of tumor hypoxia and testing of hypoxia-targeted cancer therapies in clinical trials molecular correlations with outcomes in radiation therapy, and improvements in radiation dosimetry, imaging and delivery. The majority of the members of the program have rich interactions with the Yale Cancer Cente (YCC) membership in several programs. Those interactions stimulate translational research that is in turr facilitated by other YCC Research Programs and by extensive use of Shared Resources. The numerous cancer-related grand rounds, seminars, meetings, and journal clubs sponsored by the YCC, along with the weekly Radiobiology Workshop and Journal Club and the weekly Therapeutic Radiology Grand Rounds sponsored by the program encourage the cooperation, mutual support, and cross stimulation among the component research teams, which leads to a more rapid and efficient application of the results of the research to clinical practice. Dr. Peter M. Glazer took over as Program Leader in 2002, replacing Dr. James J. Fischer, who had served as Program Leader since its inception. Dr. Patrick Sung, recruited to Yale in 2003, serves as co-Leader. Unde the new leadership, the Program has expanded to include a total of 25 faculty affiliated with nine departments and two schools, has played a role in recruiting three basic scientists and three physician investigators, anc has initiated renovation of 15,500 net square feet of laboratory space, partially funded by a $2.0 millior construction grant from the NIH awarded in 2003. Dr. Glazer also serves as PI of a T32 post-doctoral training grant in Radiation Therapy, Biology and Physics, which includes a number of YCC members both within anc outside of the Program. Since 1998, there have been 371 cancer-related publications, including 18% intra- anc 20% inter-programmatic collaborations. Overall, the 25 investigators associated with the program have peer reviewed funding of $4.1 M in annual direct costs ($6.4 M in annual total costs), including 17 R01s. Of this funding, $2.0 M (annual direct costs) comes from the NCI, including 10 R01s and the T32 training grant.

放射生物学和放射治疗 (R&R) 项目包括基础广泛、多方面的研究放射治疗、放射生物学、放射物理学和肿瘤生物学相关领域的努力。这 20 多年来，该计划一直是癌症中心核心拨款的批准组成部分。其长期目标是总体上改善癌症治疗，特别是放射治疗的有效性该计划包括广泛的活动，从基于实验室的实验研究延伸出来与八个部门相关的临床调查和特征调查员。一些关键主题包括致癌作用、遗传不稳定性和细胞生长控制的研究； DNA修复的阐明途径；肿瘤缺氧的研究以及缺氧靶向癌症疗法的临床试验测试与放射治疗结果的分子相关性以及放射剂量测定、成像的改进和交货。该计划的大多数成员与耶鲁癌症中心有丰富的互动 (YCC) 多个项目的会员资格。这些相互作用刺激了正在发生的转化研究通过其他 YCC 研究计划和共享资源的广泛使用来促进。无数的由 YCC 以及每周放射生物学研讨会和期刊俱乐部以及每周治疗放射学大查房该计划的赞助鼓励人们之间的合作、相互支持和交叉激励组成研究团队，从而更快速、更有效地应用研究成果到临床实践。 Peter M. Glazer 博士于 2002 年接替 James J. Fischer 博士担任项目负责人。自项目成立以来一直担任项目负责人。 Patrick Sung 博士于 2003 年被耶鲁大学聘用，担任联合负责人。温德在新的领导层的领导下，该计划已扩大到包括九个院系的总共 25 名教员和两所学校，在招募三名基础科学家和三名医师研究员方面发挥了作用，已开始翻修 15,500 净平方英尺的实验室空间，部分资金为 2 百万美元 2003 年获得 NIH 建设拨款。Glazer 博士还担任 T32 博士后培训的 PI 放射治疗、生物学和物理学方面的资助，其中包括一些 YCC 成员在该计划之外。自 1998 年以来，已有 371 篇与癌症相关的出版物，其中 18% 为癌症相关出版物。 20% 项目间合作。总体而言，与该项目相关的 25 名研究人员具有同行审查了年度直接成本 410 万美元（年度总成本 640 万美元）的资金，包括 17 个 R01。其中的资金方面，200 万美元（每年直接费用）来自 NCI，包括 10 个 R01 和 T32 培训补助金。